Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (41-50 of 297) with videos related to

Pageof 30
Sort By:
Current Opinion in Pulmonary Medicine|August 1, 2019
Pulmonary hypertension due to interstitial lung diseaseChristopher S King, Steven D Nathan
American Journal of Respiratory and Critical Care Medicine|July 16, 2014
Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trialSteven D Nathan, Roberto G Carbone
Thorax|November 25, 2015
Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?Steven D Nathan, Paul A Corris
The American Journal of Managed Care|November 4, 2024
Real-world data on the course of idiopathic pulmonary fibrosisSteven D Nathan, Joyce S Lee
The New England Journal of Medicine|May 12, 2021
Inhaled Treprostinil in Group 3 Pulmonary Hypertension. ReplySteven D Nathan, Aaron Waxman, Victor Tapson
Cardiology Clinics|November 23, 2021
Lung Disease-Related Pulmonary HypertensionKareem Ahmad, Vikramjit Khangoora, Steven D Nathan
Chest|May 9, 2024
ResponseSteven D Nathan, Eric Shen, Chunqin Deng
Expert Opinion on Drug Safety|May 14, 2016
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosisAdam Anderson, Adrian Shifren, Steven D Nathan
Respiratory Medicine|November 29, 2016
sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertensionRaymond Benza, Stephen Mathai, Steven D Nathan
Chest|February 3, 2011
Pulmonary complications of lung transplantationShahzad Ahmad, Oksana A Shlobin, Steven D Nathan
Pageof 30

Showing results (41-50 of 297) with videos related to

Sort By:
Pageof 30
Current Opinion in Pulmonary Medicine|August 1, 2019
Pulmonary hypertension due to interstitial lung diseaseChristopher S King, Steven D Nathan
American Journal of Respiratory and Critical Care Medicine|July 16, 2014
Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trialSteven D Nathan, Roberto G Carbone
Thorax|November 25, 2015
Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?Steven D Nathan, Paul A Corris
The American Journal of Managed Care|November 4, 2024
Real-world data on the course of idiopathic pulmonary fibrosisSteven D Nathan, Joyce S Lee
The New England Journal of Medicine|May 12, 2021
Inhaled Treprostinil in Group 3 Pulmonary Hypertension. ReplySteven D Nathan, Aaron Waxman, Victor Tapson
Cardiology Clinics|November 23, 2021
Lung Disease-Related Pulmonary HypertensionKareem Ahmad, Vikramjit Khangoora, Steven D Nathan
Chest|May 9, 2024
ResponseSteven D Nathan, Eric Shen, Chunqin Deng
Expert Opinion on Drug Safety|May 14, 2016
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosisAdam Anderson, Adrian Shifren, Steven D Nathan
Respiratory Medicine|November 29, 2016
sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertensionRaymond Benza, Stephen Mathai, Steven D Nathan
Chest|February 3, 2011
Pulmonary complications of lung transplantationShahzad Ahmad, Oksana A Shlobin, Steven D Nathan
Pageof 30